Apexigen, Inc.
APGNW
NASDAQ Capital Market0.03
USD
+0.01
- -
CIK
0001814140
Return %
Stock
S&P500
1Y
-89.11
26.53
3Y
-99.00
76.60
5Y
-99.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- IPO Date
- Feb 22, 2021
- CIK
- 0001814140
- Similar Companies
- Business
- Apexigen, Inc. was a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative antibody therapeutics for cancer, emphasizing novel immuno-oncology agents designed to engage the body's immune system against tumors. The company leveraged its proprietary APXiMAB™ discovery platform to generate a new generation of high-quality humanized antibodies. Its lead therapeutic candidate, sotigalimab (also known as APX005M), was a CD40 agonist antibody undergoing Phase 2 clinical trials for various solid tumor indications, including melanoma and liposarcoma. Clinical data indicated that sotigalimab demonstrated a favorable tolerability profile and rapid, sustained responses across several challenging cancer types. Apexigen also had additional preclinical programs and partnered initiatives, with its platform contributing to the development of other clinical-stage and even commercially available products. Initially becoming a publicly traded entity on Nasdaq in August 2022 through a business combination with a special purpose acquisition company, Apexigen operated under the ticker APGN. However, in May 2023, Pyxis Oncology, Inc. entered into a definitive agreement to acquire Apexigen in an all-stock transaction. The acquisition, completed in August 2023, aimed to integrate Apexigen's humanized antibody generation capabilities with Pyxis Oncology's Flexible Antibody Conjugation Technology, enhancing efforts in antibody-drug conjugate innovation and expanding Pyxis's clinical pipeline. The APGNW ticker represented warrants associated with the former publicly traded Apexigen.